Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review
- PDF / 525,874 Bytes
- 17 Pages / 595.276 x 790.866 pts Page_size
- 39 Downloads / 196 Views
REVIEW
Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review Jordi Grataco´s Masmitja` Susana Go´mez Castro
. Carlos M. Gonza´lez Ferna´ndez
.
. Francisco Jose´ Rebollo Laserna
Received: October 22, 2020 / Accepted: November 21, 2020 Ó Springer Healthcare Ltd., part of Springer Nature 2020
ABSTRACT Introduction: Therapeutic approaches for psoriatic arthritis (PsA) include non-pharmacologic therapies, symptomatic treatments, tumor necrosis factor inhibitors, interleukin inhibitors, cytotoxic T lymphocyte antigen 4 immunoglobulin, and Janus kinase inhibitors. This systematic review aimed to provide complete and up-to-date information on efficacy of tofacitinib in the treatment of PsA, giving special attention to non-skin manifestations (peripheral arthritis, axial disease, enthesitis, and dactylitis). Methods: A search of studies published between January 2016 and June 2020 was carried out on PubMed and Google Scholar. J. Grataco´s Masmitja` Rheumatology Department, Hospital Universitari Parc Taulı´ Sabadell, Medicine Department UAB, Barcelona, Spain C. M. Gonza´lez Ferna´ndez (&) CEIMI, Rheumatology Department, Hospital ˜o´n, Madrid, General Universitario Gregorio Maran Spain e-mail: [email protected] C. M. Gonza´lez Ferna´ndez ˜o´n, Sanitary Research Institute Gregorio Maran Universidad Complutense de Madrid, Madrid, Spain S. Go´mez Castro F. J. Rebollo Laserna Pfizer Medical Department, Alcobendas, Madrid, Spain
Results: The number of studies with tofacitinib in PsA is limited and most of them are post hoc analyses from OPAL Broaden and OPAL Beyond. Tofacitinib has been demonstrated to be efficacious for the treatment of all disease manifestations in PsA. Superior effectivity to placebo is achieved at the earliest time point evaluated, and maintained over time. Patients who switch from placebo to tofacitinib show the same improvements; however, the time to initial response is faster in patients who firstly receive tofacitinib, compared with those switching subsequently. Additional data suggest that tofacitinib may be also effective for the treatment of the axial domain. Conclusions: Tofacitinib has been demonstrated to be efficacious for the treatment of peripheral and axial involvement, enthesitis, and dactylitis manifestation in PsA. Further prospective and long-term studies are required to corroborate and complete the present results. Similarly, real-world evidence is also necessary to complement the information obtained in clinical trials, and thereby to have a better overview of real efficacy and safety of the drug. Keywords: Axial; Efficacy; Peripheral; Psoriatic arthritis; Rheumatology; Tofacitinib
Adv Ther
DIGITAL FEATURES Key Summary Points Why carry out this study? Therapeutic approaches for psoriatic arthritis include non-pharmacologic therapies, symptomatic treatments, tumor necrosis factor inhibitors, interleukin inhibitors, cytotoxic T lymphocyte antigen 4 immunoglobulin, and Janus kinase inhibitors. Tofacitinib is a Janus kinase inhibitor that is indica
Data Loading...
